Says “successfully navigating” Humira loss of exclusivity. Says executing well across all aspects of the business. Says multiple growth drivers to support long term outlook. Says continues to advance R&D pipeline. Says well positioned to deliver high single digit revenue CAGR through end of decade. Comments taken from Q1 earnings conference call.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: